Completed PHASE3 INTERVENTIONAL 3-arm NCT02498509

Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients

Sponsor: Chong Kun Dang Pharmaceutical

Conditions Rhinitis, Allergic, Perennial

Interventions CKD-342 Levocabastine HCL Mometasone furoate

Updated 6 times since 2017 Last updated: Dec 22, 2016 Started: May 31, 2015 Primary completion: Mar 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Rhinitis, Allergic, Perennial, this trial is completed. The trial is conducted by Chong Kun Dang Pharmaceutical and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chong Kun Dang Pharmaceutical

Data source: Chong Kun Dang Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Irwon-dong, South Korea